Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.

Watanabe S, Yamaguchi OU, Masumoto AI, Maeno Y, Kawashima Y, Ishimoto O, Sugawara S, Yoshizawa H, Kikuchi T, Nukiwa T, Kobayashi K.

Anticancer Res. 2018 Aug;38(8):4699-4704. doi: 10.21873/anticanres.12776.

PMID:
30061238
2.

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group.

Oncologist. 2018 Oct;23(10):1210-1217. doi: 10.1634/theoncologist.2017-0586. Epub 2018 Mar 22.

PMID:
29567820
3.

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.

Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N.

Lancet Oncol. 2017 May;18(5):663-671. doi: 10.1016/S1470-2045(17)30230-9. Epub 2017 Mar 23.

PMID:
28343976
4.

Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.

Ishimoto O, Sugawara S, Inoue A, Maemondo M, Nukiwa T.

Respir Investig. 2015 Jul;53(4):156-60. doi: 10.1016/j.resinv.2015.02.006. Epub 2015 May 4.

PMID:
26100175
5.

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).

Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group.

Lung Cancer. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16.

PMID:
25249428
6.

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T.

Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28.

PMID:
24853020
7.

Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.

Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T.

Oncologist. 2014 Apr;19(4):352-3. doi: 10.1634/theoncologist.2013-0411. Epub 2014 Mar 28.

8.

Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.

Sugawara S, Maemondo M, Tachihara M, Inoue A, Ishimoto O, Sakakibara T, Usui K, Watanabe H, Matsubara N, Watanabe K, Kanazawa K, Ishida T, Saijo Y, Nukiwa T; North Japan Lung Cancer Study Group.

Lung Cancer. 2013 Jul;81(1):91-6. doi: 10.1016/j.lungcan.2013.04.010. Epub 2013 May 1.

PMID:
23643176
9.

Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.

Matsubara N, Maemondo M, Inoue A, Ishimoto O, Watanabe K, Sakakibara T, Fukuhara T, Morikawa N, Tanaka M, Sugawara S, Nukiwa T.

Respir Investig. 2013 Mar;51(1):28-34. doi: 10.1016/j.resinv.2012.09.004. Epub 2012 Nov 13.

PMID:
23561256
10.

A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.

Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T.

Ann Oncol. 2010 Apr;21(4):800-3. doi: 10.1093/annonc/mdp384. Epub 2009 Oct 13.

PMID:
19825887
11.

Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.

Ishimoto O, Ishida T, Honda Y, Munakata M, Sugawara S.

Int J Clin Oncol. 2009 Feb;14(1):43-7. doi: 10.1007/s10147-008-0796-9. Epub 2009 Feb 20.

PMID:
19225923
12.

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T.

J Clin Oncol. 2008 Nov 20;26(33):5401-6. doi: 10.1200/JCO.2008.18.1974. Epub 2008 Oct 14.

PMID:
18854562
13.

Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings.

Sakakibara T, Saijo Y, Fukuhara T, Gomi K, Inoue A, Ishimoto O, Sugawara S, Nukiwa T.

J Thorac Oncol. 2008 Mar;3(3):311-3. doi: 10.1097/JTO.0b013e3181653cce.

14.

Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.

Ishimoto O, Sugawara S, Inoue A, Ishida T, Munakata M, Koinumaru S, Hasegawa Y, Suzuki T, Miki H, Saijo Y, Nukiwa T.

J Thorac Oncol. 2006 Nov;1(9):979-83.

15.

A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.

Inoue A, Usui K, Ishimoto O, Matsubara N, Tanaka M, Kanbe M, Gomi K, Koinumaru S, Saijo Y, Nukiwa T.

Lung Cancer. 2006 Apr;52(1):83-7. Epub 2006 Feb 14.

PMID:
16483687
16.

Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis.

Tazawa R, Hamano E, Arai T, Ohta H, Ishimoto O, Uchida K, Watanabe M, Saito J, Takeshita M, Hirabayashi Y, Ishige I, Eishi Y, Hagiwara K, Ebina M, Inoue Y, Nakata K, Nukiwa T.

Am J Respir Crit Care Med. 2005 May 15;171(10):1142-9. Epub 2005 Feb 25.

PMID:
15735059
17.

[Bronchial artery embolization can be effective for primary racemose hemangioma].

Ishimoto O, Sato N, Imai T, Nukiwa T, Ebina A.

Nihon Kokyuki Gakkai Zasshi. 2003 Nov;41(11):808-12. Review. Japanese.

PMID:
14661553
18.

High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer.

Ishimoto O, Saijo Y, Narumi K, Kimura Y, Ebina M, Matsubara N, Asou N, Nakai Y, Nukiwa T.

Oncology. 2002;63(1):70-5.

PMID:
12187074
19.

Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.

Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S.

Cancer Res. 2002 Feb 1;62(3):636-41.

20.

Mutation and expression of the p51 gene in human lung cancer.

Tani M, Shimizu K, Kawahara C, Kohno T, Ishimoto O, Ikawa S, Yokota J.

Neoplasia. 1999 Apr;1(1):71-9.

Supplemental Content

Loading ...
Support Center